Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 1998

View Archived Issues

Cytokine-suppressive antiinflammatory drugs from SKB

StressGen updates shareholders

Selective dopamine D3 receptor ligands developed at Neurogen

OraVax: Q1 1998 highlights

Penford approves spin-off of pharmaceutical business

Fuisz's EA technology improves onset of action of pain drugs

Neoprobe's ACT shows activity against HIV/AIDS in preclinical studies

Investigators discover clues to the functions of apoE

New antioxidants from Warner-Lambert

Renal effects of BG-9719 demonstrated in CHF patients and healthy volunteers

Glaxo Wellcome to distribute Cortecs' Macritonin in Greece

MDX-210 shows significant antitumor activity in prostate and kidney cancer patients

Forest's antidepressant drug is approvable

Preclinical efficacy in multiple gastrointestinal disorders reported for ALX-0600

Gd-Tex phase Ib/II interim results presented at ASCO

Icos begins phase I/II trial for antipsoriatic

TGF-beta3 proves ineffective for the treatment of oral mucositis

Long-term prevention of precancerous colonic polyp formation demonstrated for FGN-1

VUF-5087, a structurally rigid CysLT1 receptor antagonist

Eisai seeks collaborators for development of novel antipsychotic

Techniclone evaluates VEGF as a tumor marker

U.S. market introduction announced for Plavix

Fibrinogen receptor antagonists claimed by DuPont Merck

Sankyo prepares neuraminic acid compounds useful for preventing the flu

Thienopyridines for impotence, heart failure in development at Merck KGaA

Safety profile of ISIS-2302 in renal transplant patients

Results from phase II trial of Campylobacter vaccine

Nicaraven shows promise for protecting liver transplants

Capecitabine clinical data and product introduction announced at ASCO

Improved immunosuppression and synergistic effects described for malononitrilamides

BLA and MAA filed for recombinant factor VIII product for hemophilia A

Molecular Biosystems: Q4 and FY 1997 highlights

FDA approves Aggrastat, the first platelet blocker for unstable angina

Suradista, a novel distamycin derivative in phase I testing at Pharmacia & Upjohn

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...